Journal ArticleDOI
Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy
TLDR
For the NS5A protein, mutations within the interferon sensitivity determining region (ISDR) and the complete NS5 a protein may be of importance for response to interferons α-based treatment in patients infected with HCV subtype 1a/b.Citations
More filters
Patent
Albumin Fusion Proteins
TL;DR: The present invention encompasses albumin fusion proteins as discussed by the authors, as well as vectors containing these nucleic acids, host cells transformed with the nucleic acid vectors, and methods of making the fusion proteins of the invention.
Book ChapterDOI
Hepatitis C virus.
TL;DR: Serologic assays for detecting HCV infection were rapidly developed and improved following the initial discovery of the virus because of the urgent need to screen blood donors and prevent transmission.
Journal ArticleDOI
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response†
Jordan J. Feld,Santosh Nanda,Ying Huang,Weiping Chen,Maggie Cam,Susan N. Pusek,Lisa M. Schweigler,Dickens Theodore,Steven Zacks,T. Jake Liang,Michael W. Fried +10 more
TL;DR: The data suggest that ISG inducibility is important for the treatment response and that ribavirin may improve outcomes by enhancing hepatic gene responses to peginterferon, and these mechanisms may provide a molecular basis for the improved efficacy of combination therapy.
Journal ArticleDOI
An overview of HCV molecular biology, replication and immune responses
TL;DR: Molecular virology, replication and immune responses against HCV are summarized and how HCV escape from adaptive and humoral immune responses are discussed, which will be helpful for development of vaccine againstHCV and discovery of new medicines both from synthetic chemistry and natural sources.
Journal ArticleDOI
Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy
Maureen J. Donlin,Nathan A. Cannon,Ermei Yao,Jia Li,Abdus S. Wahed,Milton W. Taylor,Steven H. Belle,Adrian M. Di Bisceglie,Rajeev Aurora,John E. Tavis +9 more
TL;DR: Genetic patterns are consistent with multiple amino acid variations independently impairing the function of HCV proteins that counteract interferon responses in humans, resulting in HCV strains with variable sensitivity to therapy.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
John G. McHutchison,Stuart C. Gordon,Eugene R. Schiff,Mitchell L. Shiffman,William M. Lee,Vinod K. Rustgi,Zachary Goodman,Mei Hsiu Ling,Susannah Cort,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.
Related Papers (5)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
Peter Simmonds,Jens Bukh,Christophe Combet,Gilbert Deléage,Nobuyuki Enomoto,Stephen M. Feinstone,Phillippe Halfon,Geneviève Inchauspé,Carla Kuiken,Geert Maertens,Masashi Mizokami,Donald G. Murphy,Hiroaki Okamoto,Jean-Michel Pawlotsky,François Penin,Erwin Sablon,Tadasu Shin-I,Lieven Stuyver,Heinz-Jürgen Thiel,Sergei Viazov,Amy J. Weiner,Anders Widell +21 more